Biomerica, Inc. BMRA 深 滬
等待開盤 03-26 09:30:00 美东时间
2.16
0.000
0.00%
華盛通- 最 高2.19
- 今 開2.19
- 成交量 9083股
- 最 低 2.0579
- 昨 收 2.16
- 總市值 652.33万
- 52周最高 4.88
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 1.8664
- 委 比 56.52%
- 總股本 302.01万
- 歷史最高 187.12
- 量 比 0.24
- 振 幅 6.12%
- 歷史最低 1.8664
- 每 手 1
- 風險率 0.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 18 (Reuters) - Wall Street's main indexes were set to open l
03-18 21:11
Biomerica Receives First Commercial Order For Hp Detect, Helicobacter Pylori Diagnostic Stool Antigen Test
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe.Strategic Account: This new
03-18 20:21
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
Biomerica 收到欧洲大型实验室链对Hp Detect™的首个商业订单，该订单具有重要商业意义，可能推动欧盟更广泛市场采用。H. pylori感染在欧洲五国中50%人口中存在，被列为一级致癌物和高威胁抗药菌，市场需求持续增长。
03-18 12:19
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
Biomerica, Inc. has received UK MHRA registration for its hp+detect™ test, allowing commercial sale in Great Britain. The test detects *H. pylori*, a Class 1 carcinogen, prevalent in 45% of Europe’s population. Biomerica is actively engaging UK partners to access diagnostic markets, addressing a critical clinical need in an era of antimicrobial resistance.
03-05 13:19
Biomerica Announces Responder Analysis Results From Ongoing Real-World Study Of inFoods IBS
Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed
02-26 21:21
Vietnam's Hanoi Department of Health approves Biomerica's EZ Detect for nationwide distribution
Vietnam's Hanoi Department of Health approves Biomerica's EZ Detect for nationwide distribution Vietnam’s Hanoi Department of Health has approved Biomerica Inc.’s EZ Detect colorectal disease at-home screening test for nationwide sales and distribution in Vietnam. Biomerica said it is working with a
02-18 21:19
快讯 | 越南批准Biomerica的Ez Detect™用于全国分销。
Vietnam Approves Biomerica’s Ez Detect™ for Nationwide Distribution
02-18 21:19
Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
Biomerica's EZ Detect™ colorectal disease home screening test has received approval in Vietnam, marking the company's strategic entry into Southeast Asia's rapidly growing healthcare market. The FDA-cleared test detects an early warning sign of colorectal cancer in minutes, offering a simple and accessible solution. Vietnam faces a colorectal cancer crisis, with low survival rates highlighting the need for early detection tools. EZ Detect™'s bene...
02-18 13:19
Biomerica reports Q2 results
Biomerica press release (BMRA): Q2 net loss was $1.32 million, compared to $0.95 million in the prior year quarter. Revenue of $1.21M (-26.2% Y/Y). More on Biomerica Seeking Alpha’s Quant Rating on Bi...
01-15 06:19
快讯 | Biomerica公布2026财年第二季度财务业绩
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
01-15 06:17
